Metal-organic frameworks (MOFs) as drug carriers have many advantages than traditional drug carriers and have received extensive attention from researchers. However, how to regulate the microstructure of MOFs to improve the efficiency of drug delivery and sustained release behaviour is still a big problem for the clinical application. Herein, the authors synthesise surfactant-modified ZIF-8 nanoparticles with different microstructures by using different types of surfactants to modify ZIF-8. The surfactant-modified ZIF-8 nanoparticles have the larger specific surface area and total micropore volumes than the original ZIF-8, which enables doxorubicin (DOX) to be more effectively loaded on the drug carriers and achieve controlled drug sustained release. Excellent degradation performance of ZIF-8 nanoparticles facilitates the metabolism of drug carriers. The formulation was evaluated for cytotoxicity, cellular uptake and intracellular location in the A549 human non-small-cell lung cancer cell line. ZIF-8/DOX nano drugs exhibit higher cytotoxicity towards cells in comparison with free DOX, suggesting the potential application in nano drugs to cancer chemotherapy.

中文翻译：

---

具有可控微结构的表面活性剂改性ZIF-8的合成及其载药和缓释行为

金属有机框架（MOFs）作为药物载体比传统药物载体具有许多优势，受到了研究人员的广泛关注。然而，如何调控MOFs的微观结构以提高药物递送效率和缓释行为仍然是临床应用的一大难题。在此，作者通过使用不同类型的表面活性剂对 ZIF-8 进行改性，合成了具有不同微观结构的表面活性剂改性的 ZIF-8 纳米粒子。表面活性剂修饰的ZIF-8纳米颗粒比原ZIF-8具有更大的比表面积和总微孔体积，使阿霉素（DOX）能够更有效地负载在药物载体上，实现药物控释。ZIF-8纳米粒子优异的降解性能有利于药物载体的代谢。评估了该制剂在 A549 人非小细胞肺癌细胞系中的细胞毒性、细胞摄取和细胞内定位。与游离 DOX 相比，ZIF-8/DOX 纳米药物对细胞表现出更高的细胞毒性，表明纳米药物在癌症化疗中的潜在应用。